Medzown

Jennifer Levin Carter MD, MPH, MBA, and Jeffrey Hogan join forces in the latest issue of Employee Benefit News to explain how precision medicine fulfills fiduciary responsibility under the CAA. This is good for patients, the community at large, and the reputation of a company as a caring employer of choice.? https://lnkd.in/g5zZkayJ

We'd love to meet up at #HLTHUSA. Use this link to schedule time with R. Scott Reid https://lnkd.in/gzuvZuZm

Jennifer Levin Carter MD, MPH, MBA has a new article in Employee Benefit News explaining?how precision?medicine can help payers and self-insured employers curb the costs of life-saving cell and gene therapies. I think it's worth the time to read.

With as many as 4,000 cell, gene, and ribonucleic acid therapies estimated to be in development by 2030, group health plans are under more financial pressure than ever to find long-term solutions. Making cell and gene therapies more accessible and affordable raises the bar on stewardship because it's ultimately in members' best interest. It enables group health plans to fulfill their fiduciary responsibilities under the Consolidated Appropriations Act. ? In the third article in a series in Employee Benefit News, our founder and CEO, Jennifer Levin Carter MD, MPH, MBA, shares how precision medicine, access to advanced treatments, and clinical trials can significantly reduce expensive cell and gene therapy claims while improving care. ? https://lnkd.in/gCeXBJHk ? #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy

With high-cost claimants accounting for just 5% of the population but driving as much as half of all medical bills, precision medicine is key to improving care and significantly reducing the cost of care for people with cancer, rare diseases, and other complex, debilitating and life-threatening conditions increasingly treated with drugs like immunotherapies and cell and gene therapies. In the second article in a series in Employee Benefit News, our Founder and CEO, Jennifer Levin Carter MD, MPH, MBA shares how precision medicine and access to advanced treatments and clinical trials can significantly reduce these expensive claims while improving care. https://lnkd.in/gSqisdEN #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy

Don't miss this exciting panel discussion tomorrow morning at 10:45 ET at SCOPE's Clinical Trial in Tech Conference in Orlando, Florida. #precisionmedicine

We're #hiring a Head of Product to join our growing team. Know anyone who might be interested? https://lnkd.in/dSGBUqN4

Will you be at SCOPE’s Clinical Trial in Tech Conference? Join Jennifer Levin Carter MD, MPH, MBA, along with Arnon Horev, John Pavletic, Peter Lafer, and Brigham Hyde for the panel discussion: Representative Data on the 30th Anniversary of the NIH Revitalization Act. Learn more and register here: https://lnkd.in/eJkanrPK

Our Founder and CEO, Jennifer Levin Carter MD, MPH, MBA shares how precision medicine is one of the most promising and novel approaches to controlling excessive healthcare costs and providing a meaningful benefit through improved disease diagnosis, treatment, and prevention in the latest Employee Benefit News issue. https://bit.ly/493v3BT #precisionmedicine #healthcare #oncology #rarediseases #complexcare #healthcarecosts #employeebenefits #specialtypharmacy #cellandgenetherapy